https://orcid.org/0000-0003-1436-5089
References
- European AIDS Clinical Society (EACS) . Treatment of HIV-positive pregnant women. Pag 12; Version 7.0, October 2013. Available from: http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf (last access January 2014).
- Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission . Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal hiv transmission in the United States. Available from: http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0 (last access May 2014).
- Nachman S , Zheng N , Acosta EP , Teppler H , Homony B , Graham B , et al. Pharmacokinetics, safety, and 48-week efficacy of oral Raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014;58:413–22.
- FDA. Clears new formulation of raltegravir for infants. January 2014 Available from: http://www.medscape.com/viewarticle/818946
- Markowitz M , Morales-Ramirez JO , Nguyen B-Y , Kovacs CM , Steigbigel RT , Cooper DA , et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1–infected individuals. J Acquir Immune Defic Syndr. 2006;43:509–15.
- De Hoffer L , Di Biagio A , Bruzzone B , Sticchi L , Prinapori R , Gerbaldo D , et al. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother. 2013;25:181–3.
- Nobrega I , Travassos AG , Haguihara T , Amorim F , Brites C . Use of raltegravir in late-presenting, HIV-infected pregnant women. AIDS Res Hum Retroviruses. 2013;29:1451–4.
- Hegazi A , Hay P . HIV seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission. Int J STD AIDS. 2013;24:245–6.
- Jeantils V , Messaouden H , Carbillon L . Pregnancy and a regimen containing raltegravir: a pilot study on the materno foetal safety. In: 53rd ICAAC. September 10–13, 2013, Denver. Abstract H-1463.
- Hegazi A , McKeown D , Doerholt K , Donaghy S , Sadiq ST , Hay P . Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates. AIDS. 2012;26:2421–3.
- McKeown DA , Rosenvinge M , Donaghy S , Sharland M , Holt DW , Cormack I , et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24:2416–8.
- Clavel-Osorio C , Cazassus F , Stegmann S , Huc-Anaïs P , Lecam D , Peytavin G . One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother. Antimicrob Agents Chemother. 2013;57:6393–4.
- Clarke DF , Acosta E , Rizk M , Bryson Y , Spector SA , Mofenson L , et al. Raltegravir pharmacokinetics and safety in neonates (IMPAACT P1097). In: 20th CROI, 3–6 March 2013, Atlanta, GA, USA. p. 974. Poster abstract.
- Drug Safety Communication FDA . Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. Silver Spring, MD: Food and Drug Administration; 2011.